Currently, RNV patients with advanced ROP, PDR or RVO have been treated with retinal photocoagulation to decrease oxygen demand and relieve hypoxia,10, 11 or anti‐vascular endothelial growth factor (VEGF) therapy to inhibit neovascularization,12, 13, 14 while due to laser‐induced loss of retinal tissue, retinal photocoagulation can lead to complications, such as decreased visual acuity, diminished night vision and persistent visual field constriction.15 This evidence concerns the gene VEGFA and retinopathy of prematurity.